72 related articles for article (PubMed ID: 37848)
1. [The influence of MIF (melanocyte-stimulating hormone-release inhibiting factor) on psychomotor function and mood in parkinsonian patients. Preliminary report (author's transl)].
Schneider E; Fischer PA; Jacobi P; Reh W
Arzneimittelforschung; 1978; 28(8):1296-7. PubMed ID: 37848
[TBL] [Abstract][Full Text] [Related]
2. [Physiological trials with MIF-I in Parkinson's disease (author's transl)].
Gonce M; Barbeau A
Rev Neurol (Paris); 1978 Feb; 134(2):141-9. PubMed ID: 29330
[TBL] [Abstract][Full Text] [Related]
3. [MIF (melanocyte-stimulating hormone release-inhibiting factor) and Parkinson's disease].
Carolei A; Meco G; Casacchia M; Agnoli A
Acta Neurol (Napoli); 1976; 31(4):475-8. PubMed ID: 16441
[No Abstract] [Full Text] [Related]
4. Challenging the serotonergic system in Parkinson disease patients: effects on cognition, mood, and motor performance.
Scholtissen B; Verhey FR; Adam JJ; Weber W; Leentjens AF
Clin Neuropharmacol; 2006; 29(5):276-85. PubMed ID: 16960473
[TBL] [Abstract][Full Text] [Related]
5. Synthetic MIF analogues. Part II: Dopa potentiation and fluphenazine antagonism.
Voith K
Arzneimittelforschung; 1977; 27(12):2290-3. PubMed ID: 23795
[TBL] [Abstract][Full Text] [Related]
6. Double-blind evaluation of oral L-prolyl-Lleucyl-glycine amide in Parkinson's disease.
Barbeau A; Roy M; Kastin AJ
Can Med Assoc J; 1976 Jan; 114(2):120-2. PubMed ID: 3279
[TBL] [Abstract][Full Text] [Related]
7. [Slow-release L-dopa vs. standard L-dopa in Parkinson patients in various stages of the disease. Studies of pharmacokinetics and motor effectiveness].
Bergemann N; Baas H; Fischer PA
Nervenarzt; 1994 Apr; 65(4):250-7. PubMed ID: 8015632
[TBL] [Abstract][Full Text] [Related]
8. Neurological effects of MIF-1, MSH, and opiate peptides in clinical studies.
Kastin AJ; Ehrensing RH; Olson RD; Coy DH
Int J Neurol; 1980; 14(2-4):205-9. PubMed ID: 6152908
[No Abstract] [Full Text] [Related]
9. Effect of amantadine on some psychomotor performances in Parkinsonism. A double blind study.
Laitinen LV; Vilkki J
Ann Clin Res; 1971 Aug; 3(4):207-11. PubMed ID: 4937341
[No Abstract] [Full Text] [Related]
10. Failure of MIF-I to affect behavioral responses in patients with Parkinson's diseases under L-dopa therapy.
Caraceni T; Parati EA; Girotti F; Celano I; Frigerio C; Cocchi D; Müller EE
Psychopharmacology (Berl); 1979 Jun; 63(3):217-22. PubMed ID: 39308
[TBL] [Abstract][Full Text] [Related]
11. [Effects of intravenous administration of memantine in parkinsonian patients (author's transl)].
Fischer PA; Jacobi P; Schneider E; Schönberger B
Arzneimittelforschung; 1977 Jul; 27(7):1487-9. PubMed ID: 332193
[TBL] [Abstract][Full Text] [Related]
12. Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials.
Gunzler SA; Pavel M; Koudelka C; Carlson NE; Nutt JG
Clin Neuropharmacol; 2009; 32(2):97-102. PubMed ID: 18978495
[TBL] [Abstract][Full Text] [Related]
13. [Neuropsychological investigations on short-time effects of biperiden (Akineton) in Parkinson's Disease (author's transl)].
Schneider E; Jacobi P; Maxion H; Fischer P-A
Arch Psychiatr Nervenkr (1970); 1975 Dec; 221(1):15-28. PubMed ID: 1217975
[TBL] [Abstract][Full Text] [Related]
14. [Influence of thioridazine on cognitive, psychomotor, and reaction performance in patients with dysthymic-depressive syndrome (author's transl)].
Meyer FP; Walther H; Kühne GE
Pharmacopsychiatria; 1981 May; 14(3):94-9. PubMed ID: 7255542
[TBL] [Abstract][Full Text] [Related]
15. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
Nutt JG; Carter JH; Carlson NE
Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373
[TBL] [Abstract][Full Text] [Related]
16. Rapid antidepressant activity of melanocyte-inhibiting factor: a clinical trial.
Levy MI; DeNigris Y; Davis KL
Biol Psychiatry; 1982 Feb; 17(2):259-63. PubMed ID: 6122475
[No Abstract] [Full Text] [Related]
17. Effect of ciladopa on Parkinson's disease: a preliminary report.
Weiner WJ; Berger JR
Adv Neurol; 1987; 45():583-6. PubMed ID: 3548268
[No Abstract] [Full Text] [Related]
18. Possible aminergic mediation of MSH release and of the CNS effects of MSH and MIF-I.
Kastin AJ; Schally AV; Kostrzewa RM
Fed Proc; 1980 Sep; 39(11):2931-6. PubMed ID: 6105977
[TBL] [Abstract][Full Text] [Related]
19. Clinical investigations for emotional effects of neuropeptide hormones.
Ehrensing RH; Kastin AJ
Pharmacol Biochem Behav; 1976; 5(Suppl 1):89-93. PubMed ID: 13418
[TBL] [Abstract][Full Text] [Related]
20. Melanocyte-stimulating-hormone release-inhibiting factor-I and tardive dyskinesia.
Ehrensing RH; Kastin AJ; Larsons PF; Bishop GA
Dis Nerv Syst; 1977 Apr; 38(4):303-7. PubMed ID: 14814
[No Abstract] [Full Text] [Related]
[Next] [New Search]
